title: Combining capecitabine and bevacizumab in metastatic breast cancer: a comprehensive review.
abstract: Both capecitabine and bevacizumab are established agents in the treatment of metastatic breast cancer, but until recently clinical data supporting their use in combination were limited. We review available data on the capecitabine-bevacizumab combination in breast cancer, particularly results from the RIBBON-1 trial in the first-line setting, and we discuss these findings in light of previous studies. We also examine ongoing trials investigating capecitabine-bevacizumab combination therapy.
authors.affiliation: Mount Vernon Cancer Centre, Northwood, UK.
authors.forename: David
authors.initials: D
authors.lastname: Miles
authors.forename: Christoph
authors.initials: C
authors.lastname: Zielinski
authors.forename: Miguel
authors.initials: M
authors.lastname: Martin
authors.forename: Eduard
authors.initials: E
authors.lastname: Vrdoljak
authors.forename: Nicholas
authors.initials: N
authors.lastname: Robert
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000473:pathology; D000069287:Capecitabine; D002277:Carcinoma / Q000188:drug therapy* / Q000473:pathology; D017326:Clinical Trials, Phase III as Topic / Q000379:methods; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D006801:Humans; D009362:Neoplasm Metastasis; D016032:Randomized Controlled Trials as Topic / Q000379:methods
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D003841:Deoxycytidine; D000068258:Bevacizumab; D000069287:Capecitabine; D005472:Fluorouracil